Harvard Apparatus Regenerative Technology Inc.
Harvard Apparatus Regenerative Technology Inc.
Your view on HRGN
Overview
What the company does, where it operates, and who runs it.
About Harvard Apparatus Regenerative Technology Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Junli He
- Headquarters
- 84 October Hill Road, Holliston, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Junli He
- Headquarters
- 84 October Hill Road, Holliston, MA, US
Harvard Apparatus Regenerative Technology Inc., a clinical-stage biotechnology company, focuses on developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma, or birth defects.
Its lead product candidate is Cellspan Esophageal Implant for the treatment of severe esophageal disease.
The company's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs; and product candidates to treat conditions of the esophagus, including traumatic injury, caustic burns, tissue damage following chemoradiation therapy, birth defects, and reconstruction of the colon and uterus wound repair.
It also sells consumer health products that focuses on personal healthcare, including dietary supplements. Harvard Apparatus Regenerative Technology Inc. was formerly known as Biostage, Inc. and changed its name to Harvard Apparatus Regenerative Technology Inc. in July 2023.
The company was founded in 2009 and is headquartered in Holliston, Massachusetts.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Harvard Apparatus Regenerative Technology Inc., and the rating behind it. HRGN last traded at $1.80; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Harvard Apparatus Regenerative Technology Inc.. Starting points for Harvard Apparatus Regenerative Technology Inc.: EPS -$0.38, beta -0.13 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Harvard Apparatus Regenerative Technology Inc.. Harvard Apparatus Regenerative Technology Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Harvard Apparatus Regenerative Technology Inc.. Trailing twelve-month EPS for Harvard Apparatus Regenerative Technology Inc. stands at -$0.38. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Harvard Apparatus Regenerative Technology Inc.. Harvard Apparatus Regenerative Technology Inc. has reported as a listed company since 2013. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Harvard Apparatus Regenerative Technology Inc. valued side by side against its closest peers. Harvard Apparatus Regenerative Technology Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Harvard Apparatus Regenerative Technology Inc., and how their positions are changing. At a $30.9M market value, institutional positions materially move Harvard Apparatus Regenerative Technology Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Harvard Apparatus Regenerative Technology Inc. executives and directors. Shares of Harvard Apparatus Regenerative Technology Inc. have traded between $0.94 and $2.71 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Harvard Apparatus Regenerative Technology Inc.. Harvard Apparatus Regenerative Technology Inc. is a $30.9M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Harvard Apparatus Regenerative Technology Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Harvard Apparatus Regenerative Technology Inc.. Coverage tracks Harvard Apparatus Regenerative Technology Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.